Caris’ studies show use of molecular profiling to develop oncology therapies
US-based Caris Life Sciences has reported positive data from two studies conducted for the validation of its tumour molecular profiling approach to guide the development of therapeutic strategies.
During the studies, the firm stratified each patient’s tumour on a molecular level by using comprehensive genomic profiling plus (CGP+) in combination with Caris Molecular Intelligence.
CGP+ of DNA, RNA and proteins is intended to allow a personalised approach for immunotherapy, targeted therapy and chemotherapy.
The results from the studies are reported to have indicated more therapeutic options and improved outcomes.
Caris Life Sciences president and chief scientific officer David Spetzler said: “By identifying the molecular profile of malignant cells, we are enabling the identification of a treatment path that better targets what is causing malignant disease and thus results in better treatment selection and ultimately better patient outcomes.
“These studies provide further evidence that molecular profiling is a productive approach to assist clinicians in developing a therapeutic path for their patients, particularly in very challenging patients as included in these analyses.”
The firm analysed 389 cases with carcinoma of unknown primary ?CUP? tissue using next-generation sequencing to identify immune check-point blockade therapy’s response biomarkers such as point mutations, copy number variations, insertions / deletions, fusions and tumour mutational load (TML).
While 69 different genes were found to be mutated with incidences of 0.5% to 54%, use of a multiplex testing approach revealed 28% of CUPs with the biomarkers of response, indicating that immune checkpoint inhibitors could be beneficial for this type of carcinoma.
The firm further compared progression-free survival (PFS) on comprehensive multiplatform profiling-guided therapy to PFS during previous therapy to determine the ability of molecular profiling to guide treatment.
Data obtained from a total of 202 patients in four independent, physician-led studies showed a median PFS of 120 days with CGP+ directed therapies compared to 89.5 days in previous treatments.
The favourable outcome with CGP+ is believed to be due to the precise use of existing chemotherapeutic resources instead of expensive targeted therapies.